

Amlitelimab

Cat. No.:	HY-P99434
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Alvircept sudotox is an anti-OX40 Ligand (OX40L) monoclonal antibody (mAb). Alvircept sudotox inhibits OX40-OX40L interaction, and can be used in the research of atopic dermatitis ^{[1][2][3]} .
In Vitro	Amlitelimab (150 µg/mL) inhibits proliferation of human CD3 T cells ^[3] . Amlitelimab (150 µg/mL) $\times \times \times$ CD3 T $\times \times \times \times \times$ ^[3] MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Ana Maria Lé, et al. OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis-Focus on Rocatinlimab and Amlitelimab. *Pharmaceutics* 2022, 14(12), 2753.
- [2]. Saghari M, et al. OX40L Inhibition Suppresses KLH-driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof-of-Pharmacology for KY1005. *Clin Pharmacol Ther.* 2022 May;111(5):1121-1132.
- [3]. Tkachev V, et al. Combined OX40L and mTOR blockade controls effector T cell activation while preserving Treg reconstitution after transplant. *Sci Transl Med.* 2017 Sep 20;9(408):eaan3085.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA